PROM1 and glioblastoma: The CD133 epitope has been identified as a tumor marker for the purification of a subpopulation of GBM cells demonstrating cancer stem cell phenotypes, and in brain tumor xenografts simulates the heterogeneity of GBMs in situ [48].